logo-loader
viewCB2 Insights Inc.

CB2 Insights implements incentive program for $1.1M of outstanding warrants

The medical cannabis company wants its 11.8 million shares worth of warrants to come home to roost

Moneybags changing hands
The outstanding warrants range in value between $0.50 and $0.80 per share

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF), a data-driven medical cannabis company, is launching a warrant incentive program designed to encourage the exercise of its outstanding warrants. 

The company is offering an inducement to warrant holders who exercise their warrants by Christmas. If every warrant is exercised, the company said, CB2 expects to receive nearly $1.1 million in gross proceeds. 

The warrants, ranging in value between $0.50 and $0.80 per share, represent roughly 11.8 million shares.

READ: CB2 Insights to collaborate with FCM Global to support medical cannabis R&D in Colombia

“We are excited that CB2 Insights now has a clear cost structure that gives us full line of sight to hit profitability in Q1 2020,” said Prad Sekar, CEO of CB2 Insights. “The proceeds that will be raised from this program will allow us to manage through the seasonal pressures of our clinical operations while we continue expanding and accelerating the growth of our research and data business units.”

The Toronto-based company noted fewer than 10% of the total outstanding warrants are held by insiders.

CB2 concentrates on real-world evidence obtained from data outside randomized trials and generated during routine clinical practice. The company has created tools that engage the medical community and provide the data doctors and other professionals need to recommend with confidence cannabis-based medicines.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: CB2 Insights Inc.

Price: 0.125 CAD

CSE:CBII
Market: CSE
Market Cap: $10 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read